Latest news with #Tropis
Yahoo
01-05-2025
- Health
- Yahoo
Publication in Vaccine Highlights Fewer Adverse Events with PharmaJet Needle-free Intradermal Delivery compared to Needle and Syringe
There were significantly fewer adverse events associated with needle-free Tropis® intradermal (ID) delivery as compared to needle and syringe (N/S). Tropis ID delivery was preferred over N/S ID delivery by more than 98% of parents and healthcare staff. Seroprevalence levels were comparable between the two methods of administration. GOLDEN, Colo., May 01, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the publication of a study demonstrating the benefits of the PharmaJet Tropis needle-free system compared with N/S for ID administration of fractional dose poliovirus vaccine (fIPV). The study entitled Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba is published in Vaccine.1 In Cuba, the routine immunization (RI) schedule for polio consists of two doses of fIPV administered at 4 and 8 months of age administered intradermally with N/S. However, ID administration with N/S is relatively uncomfortable, complex and requires specific training. Improper technique can result in reduced immunogenicity.2 Tropis offers an easy to use, reliable technique that has been shown to improve coverage in Pakistan,3 Somalia4 and Nigeria,5 where it has been used to vaccinate nearly 12 million children. Tropis is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. The study measured acceptability, safety, and immunogenicity of Tropis compared to N/S administration with a total of 6,704 children vaccinated. Surveys were administered to parents/guardians (n=5260) and nurses (n=66) to evaluate satisfaction. Additionally, blood samples from vaccinated children were analyzed for neutralizing poliovirus antibody levels. The results indicated significantly fewer adverse events with Tropis (6%) than N/S (13%) (p=0.028), and Tropis was preferred over N/S by large margins by both parents (98%) and nurses (98.5%). Survey respondents cited ease of vaccination, diminished crying, and increased comfort as the benefits of Tropis. Of note, seroprevalence did not differ significantly between Tropis and N/S. This research collaboration between the Instituto Pedro Kourí (IPK) and the WHO was conducted to gain valuable insights that can be applied to curb the global circulating vaccine-derived poliovirus. Cuba has proven a useful resource and partner for polio eradication, acting as an incubator for testing new ideas and approaches. The WHO–Cuban collaboration, lasting for over 20 years, has been vital for the Global Polio Eradication Initiative (GPEI), making it possible to design innovative strategies, especially for the polio eradication endgame and for immunization policy development worldwide.6 "These results highlight that Tropis results in fewer AEs than Mantoux technique and is more acceptable. This should be very encouraging to vaccine programs aiming to take advantage of ID delivery," said Paul LaBarre, Vice President of Global Business Development, PharmaJet. "The strong performance of Tropis ID delivery is consistent with results recently seen in WHO-sponsored polio campaigns in Pakistan, Nigeria, and Somalia where Tropis has been used to administer polio vaccinations to nearly 12 million children." For more information visit the PharmaJet website Refer to Instructions for Use to ensure safe injections and to review risks. 1 Resik, S et al, Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba. Vaccine, Volume 52 (2025), 126903 2 Zehrung D, Jarrahian C, Wales A, Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 2013;31(34):3392–5. [PubMed PMID: 23176978]. 3 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 4 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 5 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 6 Resik, S et al, Cuba's Scientific Contributions to Polio Eradication. MEDICC Review, April 2018, Vol 20 No. 2, Peer Reviewed About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Cuba's role in the collaboration with the WHO and GPEI2 Cuba's part in the continuing collaboration with the World Health Organization (WHO) has focused on issues relevant to policymaking for the ongoing global polio eradication effort. It has concentrated particularly on looking for answers to scientific questions that could not be answered elsewhere, taking into account Cuba's unique OPV vaccination program, conducted only twice annually, usually in February and April. Specifically, research has addressed several aspects of OPV and inactivated poliovirus vaccine (IPV), such as immunogenicity, adverse reactions and complications, persistence of Sabin virus in populations, the immunogenicity schedule and its affordability, number of doses needed, evaluation of new vaccines and devices, and booster response. View source version on Contacts Nancy 1-888-900-4321 Option 3
Business Wire
01-05-2025
- Health
- Business Wire
Publication in Vaccine Highlights Fewer Adverse Events with PharmaJet Needle-free Intradermal Delivery compared to Needle and Syringe
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the publication of a study demonstrating the benefits of the PharmaJet Tropis needle-free system compared with N/S for ID administration of fractional dose poliovirus vaccine (fIPV). The study entitled Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba is published in Vaccine. 1 In Cuba, the routine immunization (RI) schedule for polio consists of two doses of fIPV administered at 4 and 8 months of age administered intradermally with N/S. However, ID administration with N/S is relatively uncomfortable, complex and requires specific training. Improper technique can result in reduced immunogenicity. 2 Tropis offers an easy to use, reliable technique that has been shown to improve coverage in Pakistan, 3 Somalia 4 and Nigeria, 5 where it has been used to vaccinate nearly 12 million children. Tropis is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. The study measured acceptability, safety, and immunogenicity of Tropis compared to N/S administration with a total of 6,704 children vaccinated. Surveys were administered to parents/guardians (n=5260) and nurses (n=66) to evaluate satisfaction. Additionally, blood samples from vaccinated children were analyzed for neutralizing poliovirus antibody levels. The results indicated significantly fewer adverse events with Tropis (6%) than N/S (13%) (p =0.028), and Tropis was preferred over N/S by large margins by both parents (98%) and nurses (98.5%). Survey respondents cited ease of vaccination, diminished crying, and increased comfort as the benefits of Tropis. Of note, seroprevalence did not differ significantly between Tropis and N/S. This research collaboration between the Instituto Pedro Kourí (IPK) and the WHO was conducted to gain valuable insights that can be applied to curb the global circulating vaccine-derived poliovirus. Cuba has proven a useful resource and partner for polio eradication, acting as an incubator for testing new ideas and approaches. The WHO–Cuban collaboration, lasting for over 20 years, has been vital for the Global Polio Eradication Initiative (GPEI), making it possible to design innovative strategies, especially for the polio eradication endgame and for immunization policy development worldwide. 6 'These results highlight that Tropis results in fewer AEs than Mantoux technique and is more acceptable. This should be very encouraging to vaccine programs aiming to take advantage of ID delivery,' said Paul LaBarre, Vice President of Global Business Development, PharmaJet. 'The strong performance of Tropis ID delivery is consistent with results recently seen in WHO-sponsored polio campaigns in Pakistan, Nigeria, and Somalia where Tropis has been used to administer polio vaccinations to nearly 12 million children.' For more information visit the PharmaJet website About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Cuba's role in the collaboration with the WHO and GPEI 2 Cuba's part in the continuing collaboration with the World Health Organization (WHO) has focused on issues relevant to policymaking for the ongoing global polio eradication effort. It has concentrated particularly on looking for answers to scientific questions that could not be answered elsewhere, taking into account Cuba's unique OPV vaccination program, conducted only twice annually, usually in February and April. Specifically, research has addressed several aspects of OPV and inactivated poliovirus vaccine (IPV), such as immunogenicity, adverse reactions and complications, persistence of Sabin virus in populations, the immunogenicity schedule and its affordability, number of doses needed, evaluation of new vaccines and devices, and booster response.
Mid East Info
19-02-2025
- Health
- Mid East Info
PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia - Middle East Business News and Information
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data reinforces how increased coverage, decreased cost, and acceptability can be achieved with vaccines administered with the Tropis® ID System, the first and only needle-free ID delivery technology to achieve WHO prequalification. PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia. The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia's immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global Business Development, PharmaJet. This event will bring together physicians from across the nation, along with representatives from Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, sister health professional associations, and partners. Intradermal (ID) vaccine administration can enable new vaccine strategies that leverage improved cross-protection, duration of immune response, and mucosal immunity. However, administration to the ID space has been difficult using traditional needle and syringe. Needle-free administration using the PharmaJet Tropis® ID System facilitates ID delivery with improved acceptability and speed of administration. Tropis, which has been used to administer polio vaccinations to more than 10 million children, is the first and only needle-free ID delivery technology to achieve WHO prequalification. A recent randomized controlled implementation study in Nigeria1 evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using the Tropis compared to the standard of care (SoC – full-dose, IPV intramuscular delivery with needle and syringe). The study demonstrated: Increased coverage : Among those vaccinated with Tropis, IPV2 coverage was 11.2% higher compared to the SoC. : Among those vaccinated with Tropis, IPV2 coverage was 11.2% higher compared to the SoC. Decreased total immunization costs: Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale. Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale. High acceptability: 94% caregivers reported high acceptability of Tropis. Healthcare worker preference for Tropis over the SoC was 95%. Tropis reduced administration time by five seconds on average compared to the SoC. 'The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system,' said Paul LaBarre, Vice President of Global Business Development, PharmaJet. 'Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan,2 Somalia,3 and Nigeria,4 we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' For more information visit the PharmaJet booth at the exhibition room or go to the PharmaJet website
Yahoo
19-02-2025
- Health
- Yahoo
PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data reinforces how increased coverage, decreased cost, and acceptability can be achieved with vaccines administered with the Tropis® ID System, the first and only needle-free ID delivery technology to achieve WHO prequalification. GOLDEN, Colo., February 19, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia. The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia's immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global Business Development, PharmaJet. This event will bring together physicians from across the nation, along with representatives from Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, sister health professional associations, and partners. Intradermal (ID) vaccine administration can enable new vaccine strategies that leverage improved cross-protection, duration of immune response, and mucosal immunity. However, administration to the ID space has been difficult using traditional needle and syringe. Needle-free administration using the PharmaJet Tropis® ID System facilitates ID delivery with improved acceptability and speed of administration. Tropis, which has been used to administer polio vaccinations to more than 10 million children, is the first and only needle-free ID delivery technology to achieve WHO prequalification. A recent randomized controlled implementation study in Nigeria1 evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using the Tropis compared to the standard of care (SoC - full-dose, IPV intramuscular delivery with needle and syringe). The study demonstrated: Increased coverage: Among those vaccinated with Tropis, IPV2 (second dose of the inactivated polio vaccine) coverage was 11.2% higher compared to the SoC. Decreased total immunization costs: Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale. High acceptability: 94% caregivers reported high acceptability of Tropis. Healthcare worker preference for Tropis over the SoC was 95%. Tropis reduced administration time by five seconds on average compared to the SoC. "The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system," said Paul LaBarre, Vice President of Global Business Development, PharmaJet. "Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan,2 Somalia,3 and Nigeria,4 we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs." For more information visit the PharmaJet booth at the exhibition room or go to the PharmaJet website Refer to Instructions for Use to ensure safe injections and to review risks. 1 Data on file2 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-18983 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024)4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the Medical Conference and International Health Exhibition The Ethiopian Medical Association (EMA) is organizing its 61st Annual Medical Conference and International Health Exhibition (AMC and IHE), scheduled for February 21-22, 2025, at the Haile Grand in Addis Ababa, Ethiopia. This event will bring together physicians from across the nation, along with representatives from EMA chapter offices, medical specialty societies, medical schools, the Ministries of Health and Education, sister health professional associations, and partners. Over the course of three days, the conference and exhibition will focus on raising awareness and providing education for attendees. More than 3,000 international and local trade visitors and exhibitors are expected to participate. The International Health Exhibition will serve as a unique platform, offering local and global medical companies and specialized institutions the opportunity to showcase their products and services to a broad medical audience and the general public. It will also provide an avenue for sharing the latest advancements in medical technology and health research. View source version on Contacts Nancy 1-888-900-4321 Option 3 Sign in to access your portfolio
Associated Press
19-02-2025
- Health
- Associated Press
PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia
GOLDEN, Colo.--(BUSINESS WIRE)--Feb 19, 2025-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61 st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia. The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia's immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global Business Development, PharmaJet. This event will bring together physicians from across the nation, along with representatives from Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, sister health professional associations, and partners. This press release features multimedia. View the full release here: Child receives polio immunization with the PharmaJet Tropis Needle-free Injection System as part of a recent campaign in Nigeria. (Photo: Business Wire) Intradermal (ID) vaccine administration can enable new vaccine strategies that leverage improved cross-protection, duration of immune response, and mucosal immunity. However, administration to the ID space has been difficult using traditional needle and syringe. Needle-free administration using the PharmaJet Tropis ® ID System facilitates ID delivery with improved acceptability and speed of administration. Tropis, which has been used to administer polio vaccinations to more than 10 million children, is the first and only needle-free ID delivery technology to achieve WHO prequalification. A recent randomized controlled implementation study in Nigeria 1 evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using the Tropis compared to the standard of care (SoC - full-dose, IPV intramuscular delivery with needle and syringe). The study demonstrated: Increased coverage: Among those vaccinated with Tropis, IPV2 coverage was 11.2% higher compared to the SoC. Decreased total immunization costs: Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale. High acceptability: 94% caregivers reported high acceptability of Tropis. Healthcare worker preference for Tropis over the SoC was 95%. Tropis reduced administration time by five seconds on average compared to the SoC. 'The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system,' said Paul LaBarre, Vice President of Global Business Development, PharmaJet. 'Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan, 2 Somalia, 3 and Nigeria, 4 we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' For more information visit the PharmaJet booth at the exhibition room or go to the PharmaJet website About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, and allow for a preferred patient and caregiver experience, while also being safe, fast, and easy-to-use. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit or contact PharmaJet here. [email protected] 1-888-900-4321 Option 3 SOURCE: PharmaJet Copyright Business Wire 2025. PUB: 02/19/2025 03:10 AM/DISC: 02/19/2025 03:10 AM
